ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference
ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference
WINSTON-SALEM, N.C., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in December:
WINSTON-SALEm，北卡羅來納州，2024年11月26日（環球新聞社）- ProKidney corp.（納斯達克：PROK）（"ProKidney"），一家專注於慢性腎病（CKD）首類細胞治療候選藥物開發的晚期臨床階段生物技術公司，今日宣佈管理團隊的高級成員將參加以下兩項於12月舉行的醫療保健會議：
|
Evercore HealthCONx Conference | |
| Date: | December 3, 2024 |
| Time: | 8:45am ET |
| Format: | Fireside Chat |
| Webcast: | Link |
|
Citi Global Healthcare Conference | |
| Date: | December 4, 2024 |
| Format: | One-on-one meetings |
| Evercore HealthCONx會議 | |
| 日期： | 2024年12月3日 |
| 時間： | 美東時間上午8:45 |
| 格式： | 爐邊聊天 |
| 網絡直播： | 連接 |
| 花旗全球醫療保健大會 | |
| 日期： | 2024年12月4日 |
| 格式： | 一對一會議 |
The live webcast for the Evercore fireside chat will be accessible through the "Events" section of the Investor Relations tab within ProKidney's website at . Investors interested in one-on-one meetings should contact their Evercore and/or Citi representatives.
Evercore的爐邊聊天直播將通過ProKidney網站的「投資者關係」選項卡中的「活動」部分訪問。有興趣進行一對一會議的投資者應聯繫Evercore和/或Citi代表。
About ProKidney Corp.
ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney's lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for its potential to preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. For more information, please visit .
關於ProKidney公司。
ProKidney是通過細胞治療創新治療慢性腎病的先驅，成立於2015年經過十年的研究。ProKidney的主導產品候選藥物Rilparencel（也被稱爲REACT）是一種首創的，擁有專利的自體細胞療法，在第2和第3階段的研究中評估其保護糖尿病患者腎功能的潛力。Rilparencel已獲得FDA的再生醫學先進療法（RMAT）認定。欲了解更多信息，請訪問。
Investor Contacts:
投資者聯繫方式：
ProKidney
Ethan Holdaway
Ethan.Holdaway@prokidney.com
ProKidney
Ethan Holdaway
Ethan.Holdaway@prokidney.com
LifeSci Advisors, LLC
Daniel Ferry
Daniel@lifesciadvisors.com
LifeSci Advisors, LLC
Daniel Ferry
Daniel@lifesciadvisors.com
譯文內容由第三人軟體翻譯。
